Advancing Drug Development in Hidradenitis Suppurativa (HS) Through Translational Research & Biomarker Science: Providing New Clarity to Disease State & Treatment Response
Time: 12:00 pm
day: Day Two Discovery Track AM
Details:
- HS is a highly inflammatory condition characterized by deep dermal lesions — notably draining tunnels — that are the predominant sources of inflammation, with disease activity also reflected in elevated levels of systemic inflammation
- Many aspects of HS pathogenesis remain poorly understood, posing a barrier to drug development (as reflected in numerous unsuccessful clinical trials and limited therapeutic options)
- We have pioneered translational research into disease drivers and prognostic biomarkers, through a multitude of state-of-the-art methodologies that represent a blueprint for a new paradigm of science-driven drug development in HS
